Pursuing Productive Pharma Partnerships In Korea
Executive Summary
Multinational and domestic pharma companies operating in South Korea should develop partnerships that build on each others’ strengths, delegates at a recent conference in Seoul heard.
You may also be interested in...
MSD Accesses Korea Oncology Innovation Through State Fund
In an ongoing series of joint R&D programs with big foreign pharma firms, the Korea Drug Development Fund has tied up with MSD to support the development of novel cancer therapies.
Dong-A Eyes Expanded Evogliptin Markets Via Tobira NASH Deal
Dong-A ST’s in-house developed DPP-4 inhibitor evogliptin is set to enter major markets, including the US and Europe, through a new licensing deal with Tobira that will focus on the treatment of non-alcoholic steatohepatitis (NASH) rather than diabetes.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.